首页> 外文期刊>Current respiratory medicine reviews >Cofactor Biosynthetic Pathways in Mycobacterium tuberculosis as Potential Drug Targets
【24h】

Cofactor Biosynthetic Pathways in Mycobacterium tuberculosis as Potential Drug Targets

机译:结核分枝杆菌中的辅助因子生物合成途径作为潜在的药物靶标

获取原文
获取原文并翻译 | 示例
           

摘要

There are many chemotherapeutic interventions available for tuberculosis (TB) and are in use for more than five decades, but still there is an urgent need for novel drugs against new targets due to emergence of resistant strains. Moreover, the ability of Mycobacterium tuberculosis (Mtb) to survive within granulomas in a non-replicating latent stage prolongs the course of drug dose and hence increases the severity of the disease. The significant rerouting of metabolism is one of the key processes that help mycobacteria adapt to the hostile environment of host granuloma. In this review, we are focusing on some of the cofactor biosynthetic pathways of Mycobacterium tuberculosis and their utilization as drug targets.
机译:有许多可用于治疗结核病(TB)的化学疗法,但由于耐药菌株的出现,迫切需要针对新靶标的新型药物。此外,结核分枝杆菌(Mtb)在肉芽肿中以非复制潜伏期生存的能力延长了药物剂量的过程,因此增加了疾病的严重性。代谢的显着改变路线是帮助分枝杆菌适应宿主肉芽肿的不利环境的关键过程之一。在这篇综述中,我们集中于结核分枝杆菌的一些辅助因子生物合成途径及其作为药物靶标的利用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号